Clinical trial · Observational
A Clinical Trial of Dermacorder for Detecting Malignant Skin Lesions
A Phase I Clinical Trial of Dermacorder for Detecting Malignant Skin Lesions
NCT01014819CI-TRIAL-00005308DermacordercompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The Dermacorder measures the electric field in the skin. Malignant skin lesions disrupt the skin's normal electric field and this abnormal electric field can be detected by the Dermacorder. Therefore the investigators are testing the hypothesis that the Dermacorder can provide useful data to guide in the diagnosis of skin disease.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Basal Cell Carcinoma | Basal Cell Carcinoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Study subjects must have had diagnosed at least one benign or malignant skin lesion; * Subject is from 18-75 years of age, inclusive; * Subject must sign and date all informed consent statements. Exclusion Criteria: * Subject is exhibiting signs of a bacterial or viral infection, including fever; * Subject is unwilling to allow a biopsy of a malignant lesion for histological analysis.
References
Publications (0)
Data not yet available
No reference posted for this study.